Newly launched Judo Bio aims to develop ligand-siRNA conjugates through its Selectively Targeting RNA Into KidnEy (STRIKE) ...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and Moderna, Inc. (NASDAQ:MRNA) have reached a stipulation in their ongoing ...
Alnylam Pharmaceuticals admitted defeat, for now, in a lawsuit in Delaware federal court that accused Moderna's blockbuster ...
With the business potentially at an important milestone, we thought we'd take a closer look at Alnylam Pharmaceuticals, ...
Zacks.com on MSN5d
Here's Why You Should Add ALNY Stock to Your Portfolio Right NowAlnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of ...
Camp4 Therapeutics Inc., a Cambridge biotech that has already struck deals with Biogen Inc. and Alnylam Pharmaceuticals Inc., ...
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $1,295.68 today based on a ...
Two new analyses from HELIOS-B answer important questions, but some uncertainties remain, says Julie Rosenthal.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...
US RNAi therapeutics company Alnylam Pharmaceuticals has released two new data sets from the HELIOS-B Phase III study of ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Day event on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback